Core Viewpoint - Shenzhen Hanyu Pharmaceutical Co., Ltd. (hereinafter referred to as "Hanyu Pharmaceutical") expects significant revenue growth in 2025, with projected revenue between 950 million to 980 million yuan, representing an increase of 60.96% to 66.05% year-on-year, and a net profit of 40 million to 50 million yuan, marking a turnaround from losses in the previous year [1] Group 1: Financial Performance - The company anticipates 2025 revenue of 950 million to 980 million yuan, a year-on-year growth of 60.96% to 66.05% [1] - Net profit is projected to be between 40 million to 50 million yuan, indicating a return to profitability [1] Group 2: Business Development - The growth in revenue is driven by the synergy between international formulations and active pharmaceutical ingredients, which are core engines of revenue growth [1] - The CRDMO (Contract Research, Development, and Manufacturing Organization) business is being actively advanced, contributing to the company's growth strategy [1] Group 3: Research and Innovation - Hanyu Pharmaceutical maintains a strong focus on innovation, with high R&D investment aimed at developing peptide innovative drugs, complex formulations, and cutting-edge technology platforms [1] - Significant progress has been made in multiple research projects, including the three-target innovative drug HY3003 and semaglutide, reinforcing the company's technological barriers [1] Group 4: Strategic Partnerships - The company is expanding its growth avenues through CRDMO business, leveraging its multi-national GMP certification and full industry chain capabilities [1] - Collaborations with companies like Carbon Cloud Peptide and Borui Pharmaceutical have been deepened, covering projects in areas such as antimicrobial peptides and oral peptides, successfully transforming technical accumulation into systematic service output capabilities [1]

细菌性肺炎 是全球重大的健康负担，具有高发病率和高死亡率，尤其在免疫缺陷或有既往健康问题的人群中。它是由肺实质和肺泡腔内严重的炎症所定义的，这 种炎症是由细菌病原体引发的，这些病原体与宿主的免疫防御系统复杂地相互作用。 目前，细菌性肺炎的一线治疗主要依赖经验性使用 抗生素 ，包括氟喹诺酮类、β-内酰胺类和大环内酯类。尽管这些抗生素对敏感细菌仍有效，但其临床疗效正逐 渐受到 多重耐药 （MDR） 细菌日益增多的影响，这类细菌如今在超过 25% 的肺炎病例中出现，并且与死亡率上升密切相关。 细菌清除功能缺陷会导致过度炎症，损害组织的恢复能力，并削弱宿主维持有效免疫防御的能力。这种不断加剧的炎症循环会加速疾病的发展进程，给治疗干预 带来了巨大的障碍。因此，迫切需要开发出能够同时根除多重耐药菌并减轻炎症引起的肺部损伤的创新治疗策略。 近日，西奈山伊坎医学院 董一洲 教授团队 （ 薛涌尔 、 侯续成 、 王思雨 为论文共同第一作者 ） 在 Nature 子刊 Nature Biotechnology 上发表了题为 ： Antimicrobial peptide delivery to lung as peptibody ...

撰文丨王聪 编辑丨王多鱼 排版丨水成文 世界卫生组织 （WHO） 曾发一份多重耐药菌名单，统称为 ESKAPE ， 代表了六种最棘手、最常见的多重耐药细菌， 名单之首是 耐碳青霉烯类鲍曼不动杆菌 （CRAB） 。碳青霉烯类抗生素是所有其他治疗手段都失败时的"最后一道防线"，但其极易受到抗生素耐药性的出现和传播的影响。鉴于这一紧迫问题，人们越 来越关注 抗菌肽 （AMP） 作为传统抗生素的有前景替代品。 与传统抗生素相比， 抗菌肽 （AMP） 因其广谱活性、快速杀菌机制以及诱导耐药性的可能性较小，成为很有前景的抗生素替代品。发现针对临床多重耐药菌的 新型抗菌肽，对于应对持续的抗生素耐药危机至关重要。 2025 年 10 月 3 日，山东大学齐鲁医学院 张磊 教授、 赵国平 教授团队在 Nature 子刊 Nature Microbiology 上发表了 题为： A generative artificial intelligence approach for the discovery of antimicrobial peptides against multidrug-resistant bacteria ...